Paul Weinreb, PhD

Paul Weinreb joined Metaphore in November 2025 as SVP of Biotherapeutics and Enabling Technologies.

Paul brings extensive biologics drug discovery experience in the biopharma industry and has contributed to identifying and advancing multiple antibody-based therapeutics that entered clinical development in the fields of neurodegeneration, fibrosis, and autoimmune disease. Prior to joining Metaphore, Paul spent 26 years at Biogen in positions of increasing responsibility, including most recently as the head of the Biologics Drug Discovery department, Biogen’s protein therapeutics modality unit, where he provided leadership to programs across all phases of Discovery and to early-stage clinical and commercial programs.

At Biogen, Paul led drug discovery activities for programs in Alzheimer’s and Parkinson’s diseases, fibrosis, rare diseases, and autoimmune disorders. He is a co-inventor and led drug discovery efforts on multiple programs that entered clinical development, including aducanumab (Aduhelm), the first approved treatment shown to reduce b-amyloid pathology in Alzheimer’s Disease, and antibodies to tau, alpha‐synuclein, and avb6 integrin. He also built and led a team dedicated to developing novel methods to enhance the delivery of therapeutic modalities (proteins/antibodies, oligonucleotides, and gene therapies) to tissues, including the brain.

Paul received B.S. and M.S. degrees in Chemistry from Penn State, a Ph.D. in Chemistry from the Massachusetts Institute of Technology, and was a National Institutes of Health postdoctoral fellow at Harvard Medical School.  He has coauthored more than 85 scientific papers, including high-profile publications in Science and Nature, and is an inventor on more than 20 issued US patents.